Stockreport

Incyte Reports 2019 Second Quarter Financial Results and Provides Updates on Key Clinical Programs

Incyte Corporation  (INCY) 
Last incyte corporation earnings: 2/13 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: incyte.com/ir/investor-overview.aspx
PDF Total product and royalty revenues of $510 million (+21% vs. Q2 2018) and Jakafi® (ruxolitinib) revenues of $410 million (+18% vs. Q2 2018) for the quarter ended June 30 [Read more]